Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer (FEVEX)
Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI
Sponsor: Clinical Research Technology S.r.l.
A PHASE3 clinical study on Breast Cancer and Hormone Receptor Positive Tumor, this trial is ongoing. The trial is conducted by Clinical Research Technology S.r.l. and has accumulated 7 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Dec 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinical Research Technology S.r.l.
- Consorzio Oncotech
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Asti, Italy , Bari, Italy , Benevento, Italy , Bergamo, Italy , Brindisi, Italy , Cagliari, Italy , Candiolo, Italy , Castellaneta, Italy , Catania, Italy , Catanzaro, Italy and 23 more locations